Innovent’s HK IPO draws solid demand
Innovent Biologics, the fourth issuer to ride the wave of Hong Kong’s biotechnology IPOs, was so popular with institutional investors that allocations caused a headache, said bankers.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: